AveXis — Investor Presentation (February 2018)
15 slides from AveXis's investor presentation, Feb 27, 2018
Slide 1: Disclaimers
2 This presentation contains forward-looking statements, including statements about: the timing, progress and results of preclinical studies for AVXS-201 and AVXS-301, including statements regarding the timing of preclinical studies and regulatory submissions, and our manufacturing strategy and deve
Slide 2: Executing on Our Strategy: Expanding Beyond SMA
Executing on Our Strategy: Expanding Beyond SMA 3 Rett syndrome (MECP2) and ALS (SOD1) are rare, life-threatening, neurological monogenic diseases that have significant unmet need and limited treatment options – none addressing the root cause Licensed preclinical data from NCH generated by Chief Sci
Slide 3: Rett Syndrome
Rett Syndrome 4 Rett syndrome (RTT) is a rare, neuro-developmental genetic disorder characterized by slowed growth; loss of normal movement and coordination; and loss of communication skills Median age at diagnosis for classic Rett syndrome is approximately 2.7 years Referrals to specialists are pri
Slide 4: Our Solution: AVXS-201 An Innovative Treatment Approach for Rett Syndrome
Our Solution: AVXS-201 An Innovative Treatment Approach for Rett Syndrome 5 scAAV ITR Minimal MECP2 Promoter Human MECP2 Transgene scAAV ITR KEY COMPONENTS PURPOSE Recombinant AAV9 Capsid Shell Ability to deliver via the CSF to effectively target the brain and spinal cord scAAV ITR (Self-complementa
Slide 5: One-time CSF Delivery of AVXS-201 Extended Survival in MECP2 Null Rett Mice
One-time CSF Delivery of AVXS-201 Extended Survival in MECP2 Null Rett Mice 6 65x dose range Doses ascend from lowest (Dose 1) to highest (Dose 6) 5 of 6 doses studied significantly improved survival Median survival increased from 66 days to >200 days (Data on File)
Slide 6: AVXS-201 Reduced Behavioral Abnormalities in Rett Mice
AVXS-201 Reduced Behavioral Abnormalities in Rett Mice Reduced and maintained correction of behavioral phenotypes Phenotypes Include: Tremor Gait Abnormal Respiration Mobility General Condition Hind limb Clasping Qualitative Behavioral Scoring Pathology (Guy et al. 2007 Nature) Green line indicates
Slide 7: Genetic ALS with SOD1 Mutation
Median age at diagnosis is 55 Referrals to specialists are primarily from general neurologists, with a very small number from primary care physicians Current treatment offers modest benefits but does not address the root genetic cause AveXis is investigating a gene therapy that addresses the root ca
Slide 8: Our Solution: AVXS-301 An Innovative Treatment Approach for Amyotrophic Lateral Sclerosis
Our Solution: AVXS-301 An Innovative Treatment Approach for Amyotrophic Lateral Sclerosis 9 KEY COMPONENTS PURPOSE Recombinant AAV9 Capsid Shell Ability to deliver via the CSF to effectively target the brain and spinal cord scAAV ITR (Self-complementary DNA technology) Enables rapid onset of effect
Slide 9: One-Time CSF Delivery of AVXS-301 Extended Survival in Male and Female ALS Model
One-Time CSF Delivery of AVXS-301 Extended Survival in Male and Female ALS Model 10 Control Dose 1 Dose 2 Dose 3 Dose 4 Median survival increased from ~130 days to >200 days (Society of Neuroscience, 2017) Control Dose 4 Control Dose 4 Doses ascend from lowest (Dose 1) to highest (Dose 4)
Slide 10: AVXS-301 Delayed Motor Impairment in ALS Mice
AVXS-301 Delayed Motor Impairment in ALS Mice 11 Maintained motor function through 200 days in male and female mice Hind limb Grip Strength Rotarod Performance Control (Males) Control (Females) Dose 4 (Males) Dose 4 (Females) (Data on File)
Slide 11: AVXS-301 Effectively Reduced SOD1 mRNA
AVXS-301 Effectively Reduced SOD1 mRNA 12 One-time CSF delivery of AVXS-301 in 10-year-old non-human primates reduced SOD1 (Data on File)
Slide 12: Preclinical Summary of AAV9 Gene Therapy for Rett Syndrome and ALS
Preclinical Summary of AAV9 Gene Therapy for Rett Syndrome and ALS 13 Gene therapy resulted in one of the longest living Rett syndrome and ALS mouse models reported to date, surpassing 200 days median survival Treated Rett syndrome mice displayed sustained reduction in behavioral abnormalities compa
Slide 13: Next Steps
Next Steps 14 AVXS-201 and AVXS-301 leverage AveXis’ scalable manufacturing platform by interchanging 1 plasmid Engineering runs at scale completed for AVXS-201 and AVXS-301 GMP campaign ongoing for AVXS-201 and scheduled for AVXS-301 Complete remaining IND-enabling preclinical work KOL meetings for
Slide 14: Next Steps
Next Steps AVEXIS INTENDS TO SUBMIT IND A\ IN LATE + AVXS-201 and AVXS-301 leverage AvexXis' scalable manufacturing platform by interchanging 1 plasmid = Engineering runs at scale completed for AVXS-201 and AVXS-301 = GMP campaign ongoing for AVXS-201 and scheduled for AVXS-301 + Complete remaining
Slide 15: Thank You
Thank You aveRis